Ibex Study Finds AI Highly Accurate in Cancer Identification

What You Should Know:

– The latest study from Ibex Medical Analytics and the Institut Curie, published in Nature, demonstrates how AI implementation across pathology labs can significantly improve the outcome of cancer care.

– The study analyzed Ibex’s AI-based quality control solution for breast biopsy review on over 15,000 slides over a diverse cohort. The study found the AI algorithm achieved high accuracy in identifying various types of cancer and 51 different morphological features of breast tissue.

– Breast cancer is the most common malignant disease worldwide, with over 2.26 million new cases in 2020. The cumulative probability of a woman receiving at least one false-positive biopsy over 10 years is estimated to be between 4.8% and 9.4%, emphasizing the need for accurate, timely, and objective diagnosis of this disease.

– The algorithm accurately identified invasive carcinoma and ductal carcinoma in situ (DCIS) with 93.79% specificity and 93.20% sensitivity. Additionally, the AI differentiated well between different grades and subtypes of breast cancer.

What You Should Know:

– The latest study from Ibex Medical Analytics and the Institut Curie, published in Nature, demonstrates how AI implementation across pathology labs can significantly improve the outcome of cancer care.

– The study analyzed Ibex’s AI-based quality control solution for breast biopsy review on over 15,000 slides over a diverse cohort. The study found the AI algorithm achieved high accuracy in identifying various types of cancer and 51 different morphological features of breast tissue.

– Breast cancer is the most common malignant disease worldwide, with over 2.26 million new cases in 2020. The cumulative probability of a woman receiving at least one false-positive biopsy over 10 years is estimated to be between 4.8% and 9.4%, emphasizing the need for accurate, timely, and objective diagnosis of this disease.

– The algorithm accurately identified invasive carcinoma and ductal carcinoma in situ (DCIS) with 93.79% specificity and 93.20% sensitivity. Additionally, the AI differentiated well between different grades and subtypes of breast cancer.